Emerging drugs and combination strategies for basal cell carcinoma (Q38207707)

31 August 2017

Emerging drugs and combination strategies for basal cell carcinoma (English)

1 reference

31 August 2017

2

Reinhard Dummer

1 reference

31 August 2017

Jil Dreier

1

1 reference

31 August 2017

Lea Felderer

3

1 reference

31 August 2017

Mirjam Nägeli

4

1 reference

31 August 2017

Sharon Gobbi

5

1 reference

31 August 2017

Rainer Kunstfeld

6

1 reference

31 August 2017

language of work or name

English

0 references

publication date

29 April 2014

1 reference

Expert Opinion on Emerging Drugs

31 August 2017

1 reference

31 August 2017

19

1 reference

31 August 2017

3

1 reference

31 August 2017

353-365

1 reference

A systematic review of worldwide incidence of nonmelanoma skin cancer

31 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Basal cell carcinoma: a paradigm for targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Aggressive basal cell carcinoma: presentation, pathogenesis, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Hedgehog-GLI pathway in medulloblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

The epidemiology of skin cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Emerging treatments and signaling pathway inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Sustained Hedgehog signaling is required for basal cell carcinoma proliferation and survival: conditional skin tumorigenesis recapitulates the hair growth cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Hedgehog signalling in cancer formation and maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Basal cell carcinomas: attack of the hedgehog

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

GDC-0449-a potent inhibitor of the hedgehog pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

A paracrine requirement for hedgehog signalling in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Discovery of NVP-LEQ506, a second-generation inhibitor of smoothened

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Hedgehog partial agonism drives Warburg-like metabolism in muscle and brown fat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Sonic hedgehog regulates angiogenesis and myogenesis during post-natal skeletal muscle regeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Development of PI3K inhibitors: lessons learned from early clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Emerging targeted agents in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Epidermal growth factor receptor signaling synergizes with Hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Hedgehog-EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumour-initiating pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Clinical trial did not demonstrate benefits of screening patients with cancer for distress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

MicroRNA-203 functions as a tumor suppressor in basal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Correlation of Global MicroRNA Expression With Basal Cell Carcinoma Subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Transcriptional regulation of bcl-2 mediated by the sonic hedgehog signaling pathway through gli-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

The expression and localization of bcl-2 protein in normal skin and in non-melanoma skin cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

bcl-2 expression reliably distinguishes trichoepitheliomas from basal cell carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Activation of the BCL2 promoter in response to Hedgehog/GLI signal transduction is predominantly mediated by GLI2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Expression of sonic hedgehog signaling components in hepatocellular carcinoma and cyclopamine-induced apoptosis through Bcl-2 downregulation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Mimicking the BH3 domain to kill cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Functional inhibition of BCL2 is needed to increase the susceptibility to apoptosis to SMO inhibitors in diffuse large B-cell lymphoma of germinal center subtype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

The p53-mdm-2 autoregulatory feedback loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Targeting p53 for Novel Anticancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Functions of the MDM2 oncoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

p53, the cellular gatekeeper for growth and division

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Arsenic trioxide inhibits cell growth and induces apoptosis through inactivation of notch signaling pathway in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Skin cancer risk in relation to toenail arsenic concentrations in a US population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Immunotherapy for nonmelanoma skin cancer: does it have a future?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

IFNalpha induces Fas expression and apoptosis in hedgehog pathway activated BCC cells through inhibiting Ras-Erk signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Imiquimod directly inhibits Hedgehog signalling by stimulating adenosine receptor/protein kinase A-mediated GLI phosphorylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Protein kinase A activation inhibits oncogenic Sonic hedgehog signalling and suppresses basal cell carcinoma of the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

Cancer-testis antigens and immunosurveillance in human cutaneous squamous cell and basal cell carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.914171

10.1517/14728214.2014.914171

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference